Ireland· IE-PA-EU/1/19/1354/001
Vizimpro 15 mg Film-coated tablet
A dacomitinib product containing dacomitinib monohydrate, registered in Ireland by Pfizer Europe MA EEIG. The same ATC class is registered in 11 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Dacomitinib is registered in 11 of 19 countries.
Countries holding a registration under ATC L01EB07 (dacomitinib), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Dacomitinib · ATC L01EB07
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- DACOMITINIB MONOHYDRATE
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Ireland (IE)
- ATC code
- L01EB07
- ATC class
- Dacomitinib
- Defined daily dose
- 45 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/19/1354/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
99 interactions on record for dacomitinib.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dacomitinib · interactions on record
99 records
- 21 severe
- 75 moderate
- 3 minor
Most severe, free to view
- OmeprazoleA02BC01severe
- PantoprazoleA02BC02severe
- LansoprazoleA02BC03severe
- RabeprazoleA02BC04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dacomitinib in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesVizimproPfizer Laboratories Div Pfizer Inc
- CzechiaVIZIMPROPfizer Europe MA EEIG, Bruxelles
- SpainVIZIMPRO 15 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPfizer Europe Ma Eeig
- FinlandVizimproPfizer Europe MA EEIG
- IcelandVizimproPfizer Europe MA EEIG*
- BelgiumVizimpro 15 mgPfizer Europe MA
- NorwayVizimproPfizer Europe MA EEIG
- PolandVizimproPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vizimpro
- Liechtenstein · Vizimpro
- Norway · Vizimpro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/04c7499c-c97e-47d7-8006-65f722221fce GET /v1/drugs/04c7499c-c97e-47d7-8006-65f722221fce?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01EB07"
],
"strength": null,
"pa_number": "EU/1/19/1354/001",
"substances": [
"DACOMITINIB MONOHYDRATE"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "02/04/2019",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about dacomitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.